home All News open_in_new Full Article

Sylentis (PharmaMar) recibirá una subvención de 21,1 millones de los fondos Next Generation

La compañía empleará este capital en investigar terapias para enfermedades raras y construir una nueva planta. Más información: PharmaMar propone elevar el dividendo un 23% hasta los 0,80 euros por acción


today 7 d. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics


ID: 2278608356
Add Watch Country

arrow_drop_down